MediWound Ltd. (MDWD)

Market Cap	183.51M
Revenue (ttm)	20.22M
Net Income (ttm)	-30.22M
Shares Out	10.81M
EPS (ttm)	-3.03
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	101,843
Open	16.59
Previous Close	16.53
Day's Range	16.58 - 17.14
52-Week Range	12.78 - 24.00
Beta	0.82
Analysts	Strong Buy
Price Target	32.00 (+88.46%)
Earnings Date	Mar 19, 2025

About MDWD

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically ap...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 20, 2014
• Employees: 100
• Stock Exchange: NASDAQ
• Ticker Symbol: MDWD
• Website: https://www.mediwound.com

Financial Performance

In 2024, MediWound's revenue was $20.22 million, an increase of 8.22% compared to the previous year's $18.69 million. Losses were -$30.22 million, 350.0% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for MDWD stock is "Strong Buy." The 12-month stock price forecast is $32.0, which is an increase of 88.46% from the latest price.

Price Target

$32.0

(88.46% upside)

Analyst Consensus: Strong Buy